Search Results - "Ferrante, Marc"

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.

Authors: Lenfant, Matthias Verstockt, Bram Sabino, João et al.

Source: Alimentary pharmacology & therapeutics Mar2024; Vol. 59 (5).

Journal Info: Publisher: Wiley-Blackwell ISSN: 0269-2813

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

Authors: Atreya, Raja Ferrante, Marc Panaccione, Remo et al.

Source: Journal of Crohn's & Colitis. Apr2025, Vol. 19 Issue 4, p1-11. 11p.

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

Authors: Ferrante, Marc Irving, Peter M Abreu, Maria T et al.

Source: Journal of Crohn's & Colitis. Mar2024, Vol. 18 Issue 3, p416-423. 8p.

Author Index.

Source: CPT: Pharmacometrics & Systems Pharmacology. Mar2022 Supplement S1, Vol. 11, pS43-S45. 3p.

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.

Authors: Lenfant, Matthias Verstockt, Bram Sabino, João et al.

Source: Alimentary Pharmacology & Therapeutics. Apr2024, Vol. 59 Issue 8, p1007-1008. 2p.

Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey.

Authors: Fiorino, Gionata Walsh, Alissa Adamina, Michel et al.

Source: Journal of Crohn's & Colitis. Jul2025, Vol. 19 Issue 7, p1-7. 7p.

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.

Authors: Ferrante, Marc Feagan, Brian G Panés, Julián et al.

Source: Journal of Crohn's & Colitis. Dec2021, Vol. 15 Issue 12, p2001-2010. 10p.

Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.

Authors: Fiorino, Gionata Fidalgo, Catarina Adamina, Michel et al.

Source: Journal of Crohn's & Colitis. Jul2025, Vol. 19 Issue 7, p1-8. 8p.

Serum extracellular RNAs as a noninvasive approach to differentiate inflammatory bowel disease subtypes: a proof-of-concept study.

Authors: Verstockt, Sare Sabino, João Ferrante, Marc et al.

Source: Journal of Crohn's & Colitis. May2025, Vol. 19 Issue 5, p1-7. 7p.

Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study.

Authors: Saruta, Masayuki Danese, Silvio Takatori, Yoshie et al.

Source: Intestinal Research. Apr2026, Vol. 24 Issue 2, p329-340. 12p.

Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis.

Authors: Verstockt, Bram Alsoud, Dahham Oostrom, Joep van et al.

Source: Journal of Crohn's & Colitis. May2025, Vol. 19 Issue 5, p1-8. 8p.

The Development of a Multidisciplinary Care Pathway for Patients with Inflammatory Bowel Disease Before, During and After Pregnancy.

Authors: De Dycker, Els Lenie, Sien Ceulemans, Michael et al.

Source: Journal of Clinical Medicine. Apr2025, Vol. 14 Issue 8, p2644. 16p.

Results of the Eighth Scientific Workshop of ECCO: Prevention and Treatment of Postoperative Recurrence in Patients With Crohn's Disease Undergoing an Ileocolonic Resection With Ileocolonic Anastomosis.

Authors: Ferrante, Marc Pouillon, Lieven Mañosa, Míriam et al.

Source: Journal of Crohn's & Colitis. Nov2023, Vol. 17 Issue 11, p1707-1722. 16p.

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study.

Authors: Schoefs, Elise Vermeire, Séverine Ferrante, Marc et al.

Source: Journal of Crohn's & Colitis. Mar2023, Vol. 17 Issue 3, p379-388. 10p.

IDH1‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia.

Authors: Guerini, Camilla Furlan, Daniela Ferrario, Giuseppina et al.

Source: Histopathology. Feb2024, Vol. 84 Issue 3, p515-524. 10p.

Editorial: biomarker predictors of non‐response to TNFα antagonists — the quest continues. Authors' reply.

Authors: Verstockt, Bram Vermeire, Séverine Ferrante, Marc et al.

Source: Alimentary Pharmacology & Therapeutics. Apr2019, Vol. 49 Issue 8, p1091-1092. 2p.

Long‐term risk of delayed postoperative Crohn's disease recurrence in patients with no or mild endoscopic recurrence at first assessment.

Authors: Mañosa, Míriam Rivière, Pauline de Greef, Ine et al.

Source: European Journal of Clinical Investigation. Aug2024, Vol. 54 Issue 8, p1-10. 10p.

Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.

Authors: Panaccione, Remo Ma, Christopher Jairath, Vipul et al.

Source: Journal of Crohn's & Colitis. Feb2025, Vol. 19 Issue 2, p1-11. 11p.

Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.

Authors: Vermeire, Séverine Hanzel, Jurij Löwenberg, Mark et al.

Source: Journal of Crohn's & Colitis. Apr2024, Vol. 18 Issue 4, p540-547. 8p.

Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.

Authors: Verstockt, Bram Pivorunas, Valerie Mahi, Naim Al et al.

Source: Journal of Crohn's & Colitis. Apr2024, Vol. 18 Issue 4, p493-505. 13p.